Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT05550701
Other study ID # SZSM201911012
Secondary ID
Status Completed
Phase
First received
Last updated
Start date May 5, 2021
Est. completion date July 10, 2022

Study information

Verified date July 2022
Source The Second Affiliated Hospital of Harbin Medical University
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

The National Quality Forum has endorsed at least 12 lymph node yield (LNY) as a surgical quality indicator in colorectal cancer (CRC), but the prognostic value of adequate lymphadenectomy has rarely been investigated for CRC patients with distant metastatic disease.


Description:

Data on CRC patients with synchronous liver metastasis (LM) were derived from the US Surveillance, Epidemiology, and End Results (SEER) and a Chinese registry (from two Chinese tertiary centers: The Second Affiliated Hospital of Harbin Medical University and National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College) between January 2010 and December 2017. Individual level data on patients with incident CRC were consecutively collected in both registries. The primary tumor site was divided into three subsites according to International Classification of Diseases for Oncology (ICD-O-3) topography codes: proximal colon (C18.0, C18.1, C18.2, C18.3 and C18.4), distal colon (C18.5, C18.6, C18.7) and rectum (C19.9 and C20.9). The synchronous LM were identified by imaging or histopathological examinations. Synchronous LM refers to liver lesions found within 6 months after the diagnosis of primary CRC. Patients were excluded if they did not undergo surgery for CRC, did not have data on number of LNs retrieved and their survival status was unknown.


Recruitment information / eligibility

Status Completed
Enrollment 4575
Est. completion date July 10, 2022
Est. primary completion date May 30, 2022
Accepts healthy volunteers No
Gender All
Age group 18 Years to 90 Years
Eligibility Inclusion Criteria: - Data on CRC patients with synchronous liver metastasis (LM) undergo surgery for CRC, have data on number of LNs retrieved and their survival status was known Exclusion Criteria: - Patients were excluded if they did not undergo surgery for CRC, did not have data on number of LNs retrieved and their survival status was unknown

Study Design


Related Conditions & MeSH terms


Intervention

Other:
lymph node yield
We recorded the number of lymph nodes dissected during surgery in patients with colorectal cancer

Locations

Country Name City State
China Ethics and ethics of the Second Affiliated Hospital of Harbin Medical University Harbin Heilongjiang

Sponsors (2)

Lead Sponsor Collaborator
The Second Affiliated Hospital of Harbin Medical University National Natural Science Foundation of China

Country where clinical trial is conducted

China, 

References & Publications (2)

Doll KM, Rademaker A, Sosa JA. Practical Guide to Surgical Data Sets: Surveillance, Epidemiology, and End Results (SEER) Database. JAMA Surg. 2018 Jun 1;153(6):588-589. doi: 10.1001/jamasurg.2018.0501. No abstract available. — View Citation

Thomas L, Li F, Pencina M. Using Propensity Score Methods to Create Target Populations in Observational Clinical Research. JAMA. 2020 Feb 4;323(5):466-467. doi: 10.1001/jama.2019.21558. No abstract available. — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary cancer specific survival The primary outcome was cancer specific survival (CSS), which was defined as the time interval from the synchronous LM diagnosis until cancer specific death or the end of follow-up in Chinese registry, and the CSS was defined using the SEER cause-of-death codes in SEER registry 2010.01-2017.12
See also
  Status Clinical Trial Phase
Recruiting NCT03594448 - Detection of MSI in Circulating Tumor DNA of Colorectal Carcinoma Patients
Completed NCT03986541 - AREG, EREG and EGFR: Response to Anti-EGFR Agents in Colorectal Cancer
Completed NCT01570452 - Matrilysin Expression in Different Stages of Colorectal Tumors N/A
Recruiting NCT05354817 - Impact of FOLFIRINOX Chemotherapy in IV Stage Colorectal Cancer Patients Previously Exposed to Irinotecan, Fluoropyrimidine and Oxaliplatin Phase 2
Recruiting NCT05576896 - Hydroxychloroquine in Combination With Encorafenib and Cetuximab or Panitumumab in the Treatment of Metastatic BRAF-mutated Colorectal Cancer Refractory Phase 2
Completed NCT04715061 - Impact of Aerobic Exercise on Immune Response and Side Effects of Cancer Treatments N/A
Terminated NCT03149679 - The p53 Colorectal Cancer Trial Phase 2
Enrolling by invitation NCT04149613 - Predictive and Prognostic Value of Inflammatory Markers and microRNA in Stage IV Colorectal Cancer
Completed NCT04425239 - Intermittent or Continuous Panitumumab Plus FOLFIRI for RAS/B-RAF Wild-type Metastatic Colorectal Cancer Phase 2
Completed NCT06329700 - Parenchymal Sparing Hepatectomy in Post-chemotherapy Liver Atrophy
Recruiting NCT05382741 - Adjuvant Durvalumab Plus Regorafenib vs Untreated Control in Stage IV Colorectal Cancer Patients With no Evidence of Disease (NED): VIVA Trial Phase 2
Recruiting NCT06342440 - Early Detection of Advanced Adenomas and Colorectal Cancer
Not yet recruiting NCT04917276 - Treatment Response Prediction System of mCRC Patients Based on CTC
Not yet recruiting NCT06296056 - Phase I Study of Combined Immune Cell Therapy in Patients With Stage 4 Colorectal Cancer With Metastatic Lesion Who Failed Prior Standard of Care Phase 1
Recruiting NCT04714814 - Mechanisms of Fate Evolution of Colorectal Adenocarcinoma Metastasis
Not yet recruiting NCT05451719 - Fruquintinib Plus Capecitabine Versus Capecitabine as Maintenance Therapy for Metastatic Colorectal Cancer After First-line Chemotherapy Phase 2
Completed NCT03031444 - Perioperative Chemotherapy Plus Cetuximab Versus Chemotherapy Alone for High Risk Resectable Colorectal Liver Metastasis Phase 2/Phase 3
Completed NCT05164419 - Impact de la Marge de résection Sur la Survie à Long Terme et le Taux de récidive Des Patients Atteints de Cancers Colorectaux opérés au CHUS Entre 2006 et 2016 Pour Des métastases hépatiques
Recruiting NCT05171660 - Combination With Sintilimab and XELOX+Bevacizumab as 1st Line Therapy in RAS-mutant Metastatic Colorectal Cancer Phase 3
Recruiting NCT05426005 - Cadonilimab for PD-1/PD-L1 Blockade-refractory, MSI-H/dMMR, Advanced Colorectal Cancer Phase 1/Phase 2